liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Malm, Claes
Publications (10 of 30) Show all publications
Hoglund, M., Sandin, F., Hellstrom, K., Bjoreman, M., Bjorkholm, M., Brune, M., . . . Richter, J. (2013). Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood, 122(7), 1284-1292
Open this publication in new window or tab >>Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
Show others...
2013 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 122, no 7, p. 1284-1292Article in journal (Refereed) Published
Abstract [en]

Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100 000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (andlt;70 years) and 79% for older (andgt;80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival.

Place, publisher, year, edition, pages
American Society of Hematology, 2013
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-97664 (URN)10.1182/blood-2013-04-495598 (DOI)000323392900028 ()
Note

Funding Agencies|Novartis||

Available from: 2013-09-19 Created: 2013-09-19 Last updated: 2017-12-06
Machaczka, M., Johansson, J.-E., Remberger, M., Hallbook, H., Malm, C., Lj Lazarevic, V., . . . Hagglund, H. (2012). Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?. Leukemia and Lymphoma, 53(9), 1699-1705
Open this publication in new window or tab >>Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
Show others...
2012 (English)In: Leukemia and Lymphoma, ISSN 1042-8194, E-ISSN 1029-2403, Vol. 53, no 9, p. 1699-1705Article in journal (Refereed) Published
Abstract [en]

Thirty-eight adult patients with chronic lymphocytic leukemia (CLL) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplant (allo-SCT) in Sweden between 1999 and 2007. The cumulative incidences of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD were 29% and 47%, respectively. Rates of non-relapse mortality, progression-free survival (PFS) and overall survival (OS) were 18%, 47% and 74% at 1 year, and 21%, 25% and 45% at 5 years, respectively. T-cell chimerism after transplant was measured in 31 out of 34 patients (91%) surviving beyond day + 100. Seventeen patients achieved andgt; 90% donor T-cell engraftment at 3 months after allo-SCT and, compared with the 12 patients with andlt;= 90% donor T-cell engraftment, they showed favorable PFS at 1 year (82% vs. 33%, p = 0.002) and better long-term PFS and OS (p = 0.002 and 0.046, respectively). Donor T-cell engraftment of andgt; 90% at 3 months after RIC allo-SCT for CLL seems to predict favorable short-term and long-term outcome.

Place, publisher, year, edition, pages
Informa Healthcare, 2012
Keywords
Allogeneic stem cell transplant, chronic lymphocytic leukemia, T-cell, donor engraftment
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-82050 (URN)10.3109/10428194.2012.666661 (DOI)000307301500012 ()
Available from: 2012-10-01 Created: 2012-09-28 Last updated: 2017-12-07
Baron, F., Labopin, M., Niederwieser, D., Vigouroux, S., Cornelissen, J. J., Malm, C., . . . Mohty, M. (2012). Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia, 26(12), 2462-2468
Open this publication in new window or tab >>Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation
Show others...
2012 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 26, no 12, p. 2462-2468Article in journal (Refereed) Published
Abstract [en]

This report investigated the impact of graft-versus-host disease (GVHD) on transplantation outcomes in 1859 acute myeloid leukemia patients given allogeneic peripheral blood stem cells after reduced-intensity conditioning (RIC allo-SCT). Grade I acute GVHD was associated with a lower risk of relapse (hazards ratio (HR) 0.7, P = 0.02) translating into a trend for better overall survival (OS; HR 1.3; P = 0.07). Grade II acute GVHD had no net impact on OS, while grade III-IV acute GVHD was associated with a worse OS (HR 0.4, P andlt; 0.0.001) owing to high risk of nonrelapse mortality (NRM; HR 5.2, P andlt; 0.0001). In time-dependent multivariate Cox analyses, limited chronic GVHD tended to be associated with a lower risk of relapse (HR 0.72; P = 0.07) translating into a better OS (HR 1.8; P andlt; 0.001), while extensive chronic GVHD was associated with a lower risk of relapse (HR 0.65; P = 0.02) but also with higher NRM (HR 3.5; P andlt; 0.001) and thus had no net impact on OS. In-vivo T-cell depletion with antithymocyte globulin (ATG) or alemtuzumab was successful at preventing extensive chronic GVHD (P andlt; 0.001), but without improving OS for ATG and even with worsening OS for alemtuzumab (HR 0.65; P = 0.001). These results highlight the role of the immune-mediated graft-versus-leukemia effect in the RIC allo-SCT setting, but also the need for improving the prevention and treatment of severe GVHD. Leukemia (2012) 26, 2462-2468; doi: 10.1038/leu.2012.135

Place, publisher, year, edition, pages
Nature Publishing Group, 2012
Keywords
reduced-intensity conditioning, AML, GVHD, chronic, graft-versus-leukemia effects
National Category
Engineering and Technology
Identifiers
urn:nbn:se:liu:diva-87465 (URN)10.1038/leu.2012.135 (DOI)000312186000003 ()
Note

Funding Agencies|Genzyme||Fresenius||Senior Research Associate at the National Fund for Scientific Research (FNRS) Belgium||

Available from: 2013-01-18 Created: 2013-01-18 Last updated: 2017-12-06Bibliographically approved
Lazarevic, V., Remberger, M., Hagglund, H., Juliusson, G., Omar, H., Halbook, H., . . . Johansson, J.-E. (2012). Letter: Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study [Letter to the editor]. Leukemia and Lymphoma, 53(3), 503-505
Open this publication in new window or tab >>Letter: Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study
Show others...
2012 (English)In: Leukemia and Lymphoma, ISSN 1042-8194, E-ISSN 1029-2403, Vol. 53, no 3, p. 503-505Article in journal, Letter (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Informa Healthcare, 2012
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-75716 (URN)10.3109/10428194.2011.616961 (DOI)000300451100029 ()
Available from: 2012-03-09 Created: 2012-03-09 Last updated: 2017-12-07Bibliographically approved
Nagler, A., Labopin, M., Shimoni, A., Mufti, G. J., Cornelissen, J. J., Blaise, D., . . . Mohty, M. (2012). Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. European Journal of Haematology, 89(3), 206-213
Open this publication in new window or tab >>Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT
Show others...
2012 (English)In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 89, no 3, p. 206-213Article in journal (Refereed) Published
Abstract [en]

Reduced-intensity conditioning (RIC)-alloSCT is increasingly used for acute myelogenous leukemia. Limited data are available for the comparison of peripheral blood stem cells with bone marrow for RIC-alloSCT. We used the European Group for Blood and Marrow Transplantation (EBMT) ALWP data to compare the outcome of mobilized peripheral blood stem cells (PBSC) (n = 1430) vs. bone marrow (BM) (n = 107) for acute myelogenous leukemia (AML) patients with complete remission that underwent RIC-alloSCT from compatible sibling donors. The leukemia features, the disease status, and the time from diagnosis were similar between the two groups. Engraftment was achieved in 99% and 93% in the PBSC and BM groups, respectively (P andlt; 0.0001). The day of engraftment was significantly earlier for the PBSC vs. the BM group, 15 (159) and 19 (569), respectively (P andlt; 0.001). Acute GVHD, severe GVHD (grade IIIIV) and chronic GVHD did not differ between the groups. leukemia-free survival (LFS), relapse, and non-relapsed mortality (NRM) were 51 +/- 2%, 32 +/- 1%, and 17 +/- 1% vs. 50 +/- 6%, 38 +/- 6%, and 12 +/- 3% for the PBSC and BM groups, respectively. Our results indicate faster engraftment, but no difference in GVHD, LFS, relapse, and NRM when comparing PBSC to BM grafts from sibling donors following RIC conditioning. This is the first study comparing PBSC to BM grafts in the RIC setting, analyzing a homogeneous population of patients with AML in remission. Whether PBSC should be preferred for advanced phases of the disease, where the outcome is dominated by relapse incidences, needs further investigation.

Place, publisher, year, edition, pages
John Wiley and Sons, 2012
Keywords
acute myelogenous leukemia, allogeneic stem cell transplantation, reduced-intensity conditioning, mobilized peripheral blood stem cells, remission, HLA matched sibling
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-81498 (URN)10.1111/j.1600-0609.2012.01811.x (DOI)000307476800003 ()
Available from: 2012-09-18 Created: 2012-09-18 Last updated: 2017-12-07
Abelsson, J., Merup, M., Birgegård, G., WeisBjerrum, O., Brinch, L., Brune, M., . . . Andréasson, B. (2012). The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplantation, 47(3), 380-386
Open this publication in new window or tab >>The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
Show others...
2012 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 47, no 3, p. 380-386Article in journal (Refereed) Published
Abstract [en]

Between 1982 and 2009 a total of 92 patients with myelofibrosis (MF) in chronic phase underwent allo-SCT in nine Nordic transplant centers. Myeloablative conditioning (MAC) was given to 40 patients, and reduced intensity conditioning (RIC) was used in 52 patients. The mean age in the two groups at transplantation was 46±12 and 55±8 years, respectively (P<0.001). When adjustment for age differences was made, the survival of the patients treated with RIC was significantly better (P=0.003). Among the RIC patients, the survival was significantly (P=0.003) better for the patients with age <60 years (a 10-year survival close to 80%) than for the older patients. The type of stem cell donor did not significantly affect the survival. No significant difference was found in TRM at 100 days between the MAC- and the RIC-treated patients. The probability of survival at 5 years was 49% for the MAC-treated patients and 59% in the RIC group (P=0.125). Patients treated with RIC experienced significantly less aGVHD compared with patients treated with MAC (P<0.001). The OS at 5 years was 70, 59 and 41% for patients with Lille score 0, 1 and 2, respectively (P=0.038, when age adjustment was made). Twenty-one percent of the patients in the RIC group were given donor lymphocyte infusion because of incomplete donor chimerism, compared with none of the MAC-treated patients (P<0.002). Nine percent of the patients needed a second transplant because of graft failure, progressive disease or transformation to AML, with no significant difference between the groups. Our conclusions are (1) allo-SCT performed with RIC gives a better survival compared with MAC. (2) age over 60 years is strongly related to a worse outcome and (3) patients with higher Lille score had a shorter survival.Bone Marrow Transplantation advance online publication, 9 May 2011; doi:10.1038/bmt.2011.91.

Place, publisher, year, edition, pages
Nature Publishing Group, 2012
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-75478 (URN)10.1038/bmt.2011.91 (DOI)000301338800010 ()21552298 (PubMedID)
Note

funding agencies|FOU, NU Hospital Organization||

Available from: 2012-03-05 Created: 2012-03-02 Last updated: 2017-12-07
Simonsson, B., Gedde-Dahl, T., Markevarn, B., Remes, K., Stentoft, J., Almqvist, A., . . . Porkka, K. (2011). Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood, 118(12), 3228-3235
Open this publication in new window or tab >>Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
Show others...
2011 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 118, no 12, p. 3228-3235Article in journal (Refereed) Published
Abstract [en]

Biologic and clinical observations suggest that combining imatinib with IFN-alpha may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-alpha 2b (Peg-IFN-alpha 2b) 50 mu g weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg-IFN-alpha 2b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg-IFN-alpha 2b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P = .002). The MMR rate increased with the duration of Peg-IFN-alpha 2b treatment (andlt; 12-week MMR rate 67%, andgt; 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg-IFN-alpha 2b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg-IFN-alpha 2b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent.

Place, publisher, year, edition, pages
American Society of Hematology, 2011
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-71380 (URN)10.1182/blood-2011-02-336685 (DOI)000295120900009 ()
Note
Funding Agencies|European LeukemiaNet||Novartis Pharma||Merck & Co (formerly Schering-Plough)||Regional Oncological Center, University of Uppsala||Novartis||BMS||Available from: 2011-10-14 Created: 2011-10-14 Last updated: 2017-12-08
Mustjoki, S., Richter, J., Barbany, G., Ehrencrona, H., Dybedal, I., Fioretos, T., . . . Hjorth-Hansen, H. (2011). Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+Progenitor Cell but Not At the CD34+CD38-Stem Cell Level: Results From Randomized NordCML006 Study in BLOOD, vol 118, issue 21, pp 356-356. In: BLOOD. Paper presented at 53rd ASH Annual Meeting and Exposition (pp. 356-356). American Society of Hematology, 118(21)
Open this publication in new window or tab >>Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+Progenitor Cell but Not At the CD34+CD38-Stem Cell Level: Results From Randomized NordCML006 Study in BLOOD, vol 118, issue 21, pp 356-356
Show others...
2011 (English)In: BLOOD, American Society of Hematology , 2011, Vol. 118, no 21, p. 356-356Conference paper, Published paper (Refereed)
Abstract [en]

n/a

Place, publisher, year, edition, pages
American Society of Hematology, 2011
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-75738 (URN)000299597101055 ()
Conference
53rd ASH Annual Meeting and Exposition
Available from: 2012-03-09 Created: 2012-03-09 Last updated: 2012-03-09
Lazarevic, V., Remberger, M., Hagglund, H., Hallbook, H., Juliusson, G., Kimby, E., . . . Johansson, J.-E. (2011). Letter: Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study [Letter to the editor]. American Journal of Hematology, 86(8), 709-710
Open this publication in new window or tab >>Letter: Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study
Show others...
2011 (English)In: American Journal of Hematology, ISSN 0361-8609, E-ISSN 1096-8652, Vol. 86, no 8, p. 709-710Article in journal, Letter (Other academic) Published
Abstract [en]

[No abstract available]

Place, publisher, year, edition, pages
Wiley-Blackwell, 2011
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-75447 (URN)10.1002/ajh.22071 (DOI)
Available from: 2012-03-02 Created: 2012-03-01 Last updated: 2017-12-07Bibliographically approved
Lj Lazarevic, V., Hagglund, H., Remberger, M., Wahlin, A., Hallbook, H., Juliusson, G., . . . Johansson, J.-E. (2011). Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden. LEUKEMIA and LYMPHOMA, 52(1), 69-71
Open this publication in new window or tab >>Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden
Show others...
2011 (English)In: LEUKEMIA and LYMPHOMA, ISSN 1042-8194, Vol. 52, no 1, p. 69-71Article in journal (Refereed) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Informa Healthcare, 2011
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-66129 (URN)10.3109/10428194.2010.520777 (DOI)000286901600013 ()
Available from: 2011-03-04 Created: 2011-03-04 Last updated: 2011-03-04
Organisations

Search in DiVA

Show all publications